Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism Who Completed the 12-Week Treatment Period in the Phase 2 Study, MBX-2H1002 Study (Avail-Ext)

NCT06531941 is registered in ClinicalTrials.gov with MBX Biosciences as lead sponsor.

NCT NCT06531941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06531941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism Who Completed the 12-Week Treatment Period in the Phase 2 Study, MBX-2H1002 Study (Avail-Ext)
Lead sponsor
MBX Biosciences
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2024
Completion date
May 31, 2028
Enrollment
60 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hypoparathyroidism